Your browser doesn't support javascript.
loading
Oncogenic BRAF, unrestrained by TGFß-receptor signalling, drives right-sided colonic tumorigenesis.
Leach, Joshua D G; Vlahov, Nikola; Tsantoulis, Petros; Ridgway, Rachel A; Flanagan, Dustin J; Gilroy, Kathryn; Sphyris, Nathalie; Vázquez, Ester G; Vincent, David F; Faller, William J; Hodder, Michael C; Raven, Alexander; Fey, Sigrid; Najumudeen, Arafath K; Strathdee, Douglas; Nixon, Colin; Hughes, Mark; Clark, William; Shaw, Robin; van Hooff, Sander R; Huels, David J; Medema, Jan Paul; Barry, Simon T; Frame, Margaret C; Unciti-Broceta, Asier; Leedham, Simon J; Inman, Gareth J; Jackstadt, Rene; Thompson, Barry J; Campbell, Andrew D; Tejpar, Sabine; Sansom, Owen J.
Affiliation
  • Leach JDG; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Vlahov N; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Tsantoulis P; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Ridgway RA; Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Flanagan DJ; Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
  • Gilroy K; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Sphyris N; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Vázquez EG; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Vincent DF; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Faller WJ; Gastrointestinal Stem Cell Biology Lab, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Hodder MC; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Raven A; Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Fey S; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Najumudeen AK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Strathdee D; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Nixon C; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Hughes M; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Clark W; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Shaw R; Cancer Research UK Beatson Institute, Glasgow, UK.
  • van Hooff SR; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Huels DJ; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Medema JP; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Frame MC; Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM) and Cancer Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
  • Unciti-Broceta A; Oncode Institute, Academic Medical Center, Amsterdam, The Netherlands.
  • Leedham SJ; Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM) and Cancer Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
  • Inman GJ; Oncode Institute, Academic Medical Center, Amsterdam, The Netherlands.
  • Jackstadt R; Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM) and Cancer Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
  • Thompson BJ; Oncode Institute, Academic Medical Center, Amsterdam, The Netherlands.
  • Campbell AD; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK.
  • Tejpar S; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Sansom OJ; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Nat Commun ; 12(1): 3464, 2021 06 08.
Article in En | MEDLINE | ID: mdl-34103493
ABSTRACT
Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair and TGFß signalling. Here, we describe a mouse model of right-sided colon cancer driven by oncogenic BRAF and loss of epithelial TGFß-receptor signalling. The proximal colonic tumours that develop in this model exhibit a foetal-like progenitor phenotype (Ly6a/Sca1+) and, importantly, lack expression of Lgr5 and its associated intestinal stem cell signature. These features are recapitulated in human BRAF-mutant, right-sided CRCs and represent fundamental differences between left- and right-sided disease. Microbial-driven inflammation supports the initiation and progression of these tumours with foetal-like characteristics, consistent with their predilection for the microbe-rich right colon and their antibiotic sensitivity. While MAPK-pathway activating mutations drive this foetal-like signature via ERK-dependent activation of the transcriptional coactivator YAP, the same foetal-like transcriptional programs are also initiated by inflammation in a MAPK-independent manner. Importantly, in both contexts, epithelial TGFß-receptor signalling is instrumental in suppressing the tumorigenic potential of these foetal-like progenitor cells.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Receptors, Transforming Growth Factor beta / Colonic Neoplasms / Proto-Oncogene Proteins B-raf / Carcinogenesis Type of study: Prognostic_studies Limits: Animals Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2021 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Receptors, Transforming Growth Factor beta / Colonic Neoplasms / Proto-Oncogene Proteins B-raf / Carcinogenesis Type of study: Prognostic_studies Limits: Animals Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2021 Document type: Article Affiliation country: